Dupixent ® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Regeneron and Sanofi announced positive Phase 4 trial results for Dupixent in treating moderate-to-severe atopic dermatitis in adults and adolescents with skin of color, a population where the disease often presents differently and is underestimated. The DISCOVER trial showed that 76% of patients achieved a 75% or greater improvement in overall disease severity (EASI-75) after 24 weeks, with significant reductions also observed in itch and hyperpigmentation. These findings support Dupixent's efficacy across various skin tones and enhance the clinical understanding of atopic dermatitis in underserved communities.

Analysis

Regeneron Pharmaceuticals and Sanofi have presented positive results from the DISCOVER Phase 4 trial for Dupixent, evaluating its efficacy in adults and adolescents with moderate-to-severe atopic dermatitis specifically within skin of color populations. This is a significant development as it represents the first large clinical trial results for Dupixent in this demographic, where atopic dermatitis often presents with unique clinical features like hyperpigmentation and may be underdiagnosed or its severity underestimated. The trial met its primary endpoint, with 76% of patients achieving a 75% or greater improvement in overall disease severity (EASI-75) at 24 weeks. Furthermore, 53% of patients experienced a clinically meaningful improvement in itch, and there was a notable 53% reduction from baseline in post-inflammatory hyperpigmentation. Patient-reported dry skin bother also significantly decreased, with only 18% remaining very or extremely bothered compared to 78% at baseline. The safety profile observed in the DISCOVER trial was generally consistent with Dupixent's known profile in approved dermatological indications, with common adverse events including headache (3%) and conjunctivitis (3%). These findings, which received a 'strongly positive' sentiment score (0.75 general, 0.8 for REGN and SNY) and a moderate market impact score (0.6), underscore Dupixent's efficacy across diverse skin tones and contribute to a deeper clinical understanding of atopic dermatitis in historically underserved communities, potentially broadening the drug's utility and market reach.

Key Decisions for Investors

• The positive DISCOVER trial data for Dupixent in patients with skin of color reinforce the drug's strong market position and growth trajectory, potentially expanding its addressable patient population and bolstering future revenue for both Regeneron and Sanofi.
• Investors should consider these results as a positive catalyst that further de-risks Dupixent's outlook and highlights its potential to address unmet needs in diverse demographic segments, which could drive continued market share gains.
• Monitor for potential updates to clinical guidelines or expanded marketing efforts based on these findings, as this could accelerate Dupixent's adoption within communities of color and contribute to sustained growth for this key franchise.